T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

Janux Therapeutics has partnered with Bristol Myers Squibb in a global licensing and collaboration deal to advance a ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy ...

Acute graft-versus-host disease (aGVHD) is a life-threatening complication after allogeneic hematopoietic stem cell ...

A new multi-pronged antibody design could help immune cells receive stronger activation signals against cancer. Researchers at the University of Southampton have identified a new strategy that could ...

Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated mCRPC patients Preliminary results are encouraging with deep ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...